[go: up one dir, main page]

DK3169334T3 - Rna til anvendelse til behandling af ledbånds- eller senelæsioner - Google Patents

Rna til anvendelse til behandling af ledbånds- eller senelæsioner Download PDF

Info

Publication number
DK3169334T3
DK3169334T3 DK15747397.6T DK15747397T DK3169334T3 DK 3169334 T3 DK3169334 T3 DK 3169334T3 DK 15747397 T DK15747397 T DK 15747397T DK 3169334 T3 DK3169334 T3 DK 3169334T3
Authority
DK
Denmark
Prior art keywords
tense
injuries
rna
link
treatment
Prior art date
Application number
DK15747397.6T
Other languages
English (en)
Inventor
Günther Hasenpusch
Carsten Rudolph
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Application granted granted Critical
Publication of DK3169334T3 publication Critical patent/DK3169334T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15747397.6T 2014-07-16 2015-07-16 Rna til anvendelse til behandling af ledbånds- eller senelæsioner DK3169334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177302 2014-07-16
PCT/EP2015/066329 WO2016009000A1 (en) 2014-07-16 2015-07-16 Rna for use in the treatment of ligament or tendon lesions

Publications (1)

Publication Number Publication Date
DK3169334T3 true DK3169334T3 (da) 2021-07-05

Family

ID=51178781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15747397.6T DK3169334T3 (da) 2014-07-16 2015-07-16 Rna til anvendelse til behandling af ledbånds- eller senelæsioner

Country Status (5)

Country Link
US (2) US10272161B2 (da)
EP (1) EP3169334B1 (da)
DK (1) DK3169334T3 (da)
ES (1) ES2879606T3 (da)
WO (1) WO2016009000A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
ES2879606T3 (es) * 2014-07-16 2021-11-22 Ethris Gmbh ARN para su uso en el tratamiento de lesiones de ligamentos o tendones
US10335498B2 (en) 2014-12-29 2019-07-02 University Of Iowa Research Foundation RNA based biomaterial for tissue engineering applications
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
AU2024293527A1 (en) * 2023-07-07 2025-12-04 The Chinese University Of Hong Kong Method of producing fabp4 inhibitor-loaded biomaterial and application for the treatment of tendon and ligament injuries

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
WO2007103787A2 (en) 2006-03-03 2007-09-13 Wyeth Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation
DK2459231T3 (da) 2009-07-31 2016-09-05 Ethris Gmbh Rna med en kombination af umodificerede og modificerede nukleotider til proteinekspression
ES2879606T3 (es) * 2014-07-16 2021-11-22 Ethris Gmbh ARN para su uso en el tratamiento de lesiones de ligamentos o tendones

Also Published As

Publication number Publication date
US11065346B2 (en) 2021-07-20
US20170189552A1 (en) 2017-07-06
US10272161B2 (en) 2019-04-30
EP3169334B1 (en) 2021-04-28
EP3169334A1 (en) 2017-05-24
US20190381193A1 (en) 2019-12-19
ES2879606T3 (es) 2021-11-22
WO2016009000A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3302478T3 (da) Pac-1 kombinations behandling
DK3169334T3 (da) Rna til anvendelse til behandling af ledbånds- eller senelæsioner
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner